t hromboembolism is a multifactorial disease involving genetic predispositions, underlying disorders, and varied triggers including infection or injury. Vascular, circulatory, and hemostatic conditions are distinctively associated with the development of arterial and venous thromboses. Thromboembolism, formerly recognized as a rare event in children (1) , has been increasingly diagnosed as a complication of sepsis, cancer, cardiovascular disease, and therapyrelated events. Recent advances in the intensive cares, cardiac surgery, and transplantation medicine along with the imaging diagnosis may contribute to the increased number of pediatric patients with thrombosis (2, 3) . The established genetic risks of venous thromboembolism (VTE) include protein C (PC), protein S (PS), and antithrombin (AT) deficiency, as well as factor V G1691A (FVL) and prothrombin G20210A (FII) variants (4) . The high incidence of VTE in Caucasians (5) is explained by the fact that FVL and FII G20210A carriers were found in 20-60% of adult VTE patients in Caucasian but not Asian ancestries (6) (7) (8) (9) . PC, PS, and AT deficiencies share the lower prevalence than FVL and/or FII G20210A carriers, but the higher risk of the first and recurrent VTE than the other thrombophilias. On the other hand, the diagnosis is challenging during infancy and early childhood, because the references of increasing anticoagulant activity range widely until adolescence (10, 11) . The true effect of the natural anticoagulant deficiencies on the development of pediatric thromboembolism remains elusive because of the rare occurrence and the elaborative genetic screenings.
To clarify the clinical impact of the inherited deficiency of natural anticoagulant on children, we conducted the genetic analysis of PC, PS, and AT deficiency after the screening of each activity for pediatric patients with thromboembolism over 20 y in a single institution. The results demonstrated the distinct presentation of PC and PS deficiencies in infants and children, respectively, reflecting the genotype of adult Japanese patients.
RESULTS

Distribution of Thromboembolic Patients
Of 306 patients aged ≤20 y (male: female 1:1.14), 186 suffered from intracranial lesions including ischemic and/or hemorrhagic strokes. The extracranial lesions consisted of renal vein thrombosis (n = 7), purpura fulminans (n = 3), deep vein thrombosis in the leg (n = 15), and pulmonary thromboembolism (n = 9). Patients younger than 3 y were 27% of all patients. The largest age group was <1 y of age (n = 50, 16.3%), and the number of other age groups were similar (median: 12, ranging: 9-17 (3.0-5.5%)).
PC, PS, and AT Activities in Patients
A total of 122 patients had the reduced activity of either anticoagulant; 95 with low PC (31%), 48 with low PS (16%), and 20 patients with low AT activity (7%; Figure 1 ). Low PC patients were most frequently determined in the lowest age group (0-2 y, 45%), while low PS or low AT patients were frequently found in the highest age group (16-20 y; PS: 30% and AT: 20%). The number of patients with low activity in age groups are shown in Figure 2 . The proportions of low PC patients were higher than those of low PS or AT patients in age 0-2 (each <0.00001) and 13-15 y (0.0001, 0.0155), respectively. The proportion of low PC or PS patients (19%) was each higher than that of low AT patients in 7-12 y (0.0005). The number of patients showing both low levels of PC and PS activities were 25 (20%), 5 of whom had the low levels of all three factors (Supplementary Figure S1 online).
Mutations of PC, PS, and AT Genes in Patients
Of 62 children who showed the low level of at least one factor, mutation carriers were found in low PC (n = 8/39, 21%), PS (n = 8/27, 30%), or AT (n = 2/5, 40%) patients, respectively. Forty-four patients carried no mutations. Age distribution of 62 patients differed among three deficiencies (0.0042; Figure 3 ). The proportion of age 0-2 y patients with PC deficiency (44%) was the highest among any age group patients with PS or AT deficiency. Six of eight patients with PC gene mutations (75%) were found in the age group 0-2 y, in which only two PS and no AT mutation carriers were determined. Four of eight patients with PS gene mutations (50%) were found in the age group 7-12 y. No ratio of mutated to analyzed patients differed in the age-groups.
Clinical Onset, Genotype, and Activity Levels of PC, PS, and AT in the Mutation Carriers
Eighteen patients with a mutation are listed in Table 1 . Seven out of eight PC-deficient patients suffered from intracranial thromboembolism and five of them were younger than 2 y. On the other hand, six of eight PS-deficient patients presented in the second decade of life, the onset of which were adult type deep vein thrombosis of pulmonary thromboembolism in five of them. Double allele (homozygous or compound heterozygous) and one allele (heterozygous) mutation(s) were found in half of eight PC-deficient patients, respectively. On the other hand, double allele mutated patients were only two of eight heritable PS-deficient patients, both of whom carried PS-Tokushima. Two other patients had PS-Tokushima. Both patients with heritable AT deficiency carried heterozygote AT mutation. Four of eight patients with PC gene mutation and Figure 1 . Flowchart of the genetic study of pediatric thrombophilia in a Japanese institution. During the 20 y, 306 patients (≤20 y of age) were screened by the plasma activities of protein C (PC), protein S (PS), and antithrombin (AT) and underwent the genetic study if they have idiopathic or unusual thrombophilic predispositions. Figure 2 . Proportion of patients who showed the low plasma activity of PC, PS, and AT according to the age groups. 0-2 y: infants (n = 84; low PC, 45%; low PS, 8%; low AT, 5%), 3-6 y: preschoolers (n = 53; low PC, 14%; low PS, 8%; low AT, 4%), 7-12 y: elementary school children (n = 73; low PC, 19%; low PS, 19%; low AT, 1%), 13-15 y: junior high school students (n = 41; low PC, 44%; low PS, 17%; low AT, 5%), 16-20 y: high school and college or university students (n = 55; low PC, 33%; low PS, 30%; low AT, 20%). Closed bar represents the patients who showed each low plasma activity. *P = 0.0155; **P = 0.0005, † P = 0.0001; ‡ P < 0.00001. ns, no statistical significance. 
DISCUSSION
The first survey on PC, PS, and AT deficiency in Japanese thromboembolic children revealed the contribution to 5.9% of pediatric thrombosis, and the age-dependent presentation of each PC, PS, or AT deficiency before adult life. Congenital PC and PS deficiencies were the major thrombophilias in Japanese children with different age distribution. Predominant cerebral thromboembolism in PC-deficiency contrasted sharply with extracranial VTE in the other two deficiencies. The (12, 13) . The Israeli-German cohort studies (14) (15) (16) have recently reported the prevalence of congenital deficiencies PC (7.4%), PS (8.2%), and AT (6.6%) in pediatric patients with thromboembolism aged 0.1-18 y. In the cohorts, the proportion of neonates was also higher in PC deficiency (32%; 8/25 patients) than seen in PS deficiency (10%; 3/30 patients) or AT deficiency (14%; 3/21 patients). Half of PC-deficient newborns presented cerebral sinovenous thrombosis and stroke. In this setting, PC-deficient infants characterized the phenotype of pediatric thrombophilias (purpura fulminans and intracranial lesions) beyond the ethnicity (17) . The age-specific prevalence and phenotype of pediatric PC deficiency may be useful in the genetic screening for pediatric thrombophilias. The first concern is the applicability of the lower limits of PC, PS, or AT activity in age groups for the genetic screening. The ranges of anticoagulant activities often vary until the attainment of adult levels, reflecting the individual maturation and vitamin K status (18, 19) . Our previous adult study assessed by the same measures reported that half of VTE patients with each low activity carried the heterozygous mutation, which resulted in 33% positive rate of all patients (20) . Miyata et al. (21) confirmed that 32% of adult VTE patients carried heterozygous mutation of PC, PS, or AT, in the twice sample size, without the screening of plasma activity. In this setting, the concordant mutation rate by the independent studies would warrant the utility of plasma activities for genetic screening in Japanese children. No mutation in >30% of patients raises the possibility of large gene deletions, polymorphisms, and the other genetic variations or certain modifiers affecting the activity and antigen concentration (22) . The present measures studied polymorphisms including the promoter regions but not deletions. Large deletions are reported to be 3-6% in these deficiencies (5). Cooper et al. (23) revealed that large deletions make up between 7 and 10% of PS and AT mutations and only 1% of PC mutations. The rare occurrence of thrombosis and the wide range of factor activities impeded to define the standard values of "true healthy" children who develop no thromboembolism until the forties. In this study, there was no significant difference in the ratios of mutated patients to the low PC patients who underwent the genetic analysis and in the ratios of mutated patients to the low PS patients analyzed in any age groups. Taking into account high safety margins, the limits of factor activity might be practical for the genetic screening of pediatric thrombophilias.
The proportion, genotype, and first presentation of PC, PS, and AT deficiency during childhood were distinct from those of adult patients. Patients with low PC activity were almost twice the number of those showing low PS activity (Figure 1) . On the other hand, the number of patients who carried either PROC or PROS1 mutation was the same eight. The first nationwide survey for pediatric thrombophilia in Japan suggested a higher prevalence of PC deficiency than expected (24, 25) . The discrepancy may be explained by the wider range of PC activity than that of PS or AT activity in infant and children (18, 26) , partly arising from the inherent variation of PC pathway (27, 28) . Clinical manifestation and thrombin generation differ among the family members having the same PROC mutation (29) . Otherwise, absolute PC deficiency rather than PS deficiency may contribute to the development of thromboembolism in the newborn and young infants (30) . Half of the PS gene-mutated patients carried PS-Tokushima, two of whom had compound heterozygous mutations with one allele PS-Tokushima ( Table 1) . Both patients lacked PS activity and developed deep vein thrombosis at 12 and 16 y of age. These findings suggested that high allele frequency of PS-Tokushima made an impact on the genotype of severe PS-deficient children in Japan. By contrast, six of eight patients with PC deficiency presented in infancy, four of whom carried double allele mutation (one PC-Nagoya) having undetectable plasma activity. The genotypes of pediatric PC and PS deficiency corroborated the previous studies on Japanese adult population.
The other concern is the distinct affected site between PC-deficient (intracranial lesion) and PS-deficient children (extracranial VTE). Premature infants with perinatal complications are liable to bleed in the brain. However, intracranial lesions including sinovenous thrombosis were also observed in adolescence ( Table 1 ). The expression levels of endothelial PC receptor and thrombomodulin are constitutively low in the brain compared with other organs. In contrast to the basilar arteries or choroid plexus, intracerebral vascular endothelium does not express thrombomodulin (31) . Free PS works as a cofactor of activated PC in the PC pathway. Circulating free PS molecules are relatively high in infancy because of physiologically low C4-binding protein levels (26) . It may explain the preferential cerebral lesions in PC-deficient children. Activated PC and thrombomodulin have homeostatic signals critical in regulating coagulation, inflammation, endothelial barrier function, and neuroprotection (32) . PC-deficient children might be vulnerable to the brain damage in association with prothrombotic triggers.
One of the limitations in this report was that the results were obtained from a single center study. The number of mutation carriers was small even in the prolonged study. The other limitation was that the consumption effects and/or the plasma replacement therapy might not be completely excluded in assessing the activity levels of the natural anticoagulants. The shorter biological half-life of PC than that of PS or AT might influence the dissociated low activity of PC in infants. However, these findings do not explain the distinct presentation between PC deficiency in infancy and PS deficiency in adolescents or young adults. Multiplex ligation-dependent probe amplification and/or single-nucleotide polymorphism array are needed to search the deletion in the future study. Further comparative study on PC-and PS-deficient infants may shed some light on the pathophysiology and optimal management of pediatric thrombophilias.
In conclusion, PC gene-mutated patients mostly presented with intracranial thromboembolism less than 2 y of age. On the other hand, PS/AT gene-mutated patients were preferentially found in school age children with extracranial VTE.
